FierceBiotech Mar 26, 2026 Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
FierceBiotech Mar 26, 2026 Biopharma funding dropped 20% in 2025 as companies doubled down on big bets: IQVIA
FierceBiotech Mar 25, 2026 FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
FierceBiotech Mar 25, 2026 Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
FierceBiotech Mar 25, 2026 After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets
FierceBiotech Mar 25, 2026 BrightGene's oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data
FierceBiotech Mar 25, 2026 Novo Nordisk prepares to go global as triple-G prospect passes midphase diabetes test in China
FierceBiotech Mar 24, 2026 Medtronic, Biotronik heart hardware make strides in conduction system pacing
FierceBiotech Mar 24, 2026 Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream
FierceBiotech Mar 24, 2026 Ocugen eye disease gene therapy hits ph. 2 targets but underwhelms investors
FierceBiotech Mar 24, 2026 Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos
FierceBiotech Mar 24, 2026 Aardvark halts trials of obesity candidate, putting entire pipeline on pause